Optimal dosing of intravascular low-power red laser light as an adjunct to coronary stent implantation: insights from a porcine coronary stent model.

BACKGROUND: It is believed that restenosis following coronary interventions is the result of endothelial denudation that leads to thrombus formation, vascular remodeling, and smooth muscle cell proliferation. Low-power red laser light (LPRLL) irradiation enhances endothelial cell growth in vitro and in vivo, and reduces restenosis in animal models. The present study investigated the optimal dose of intravascular LPRLL therapy in the prevention of in-stent stenosis in a porcine coronary stent model. METHODS AND RESULTS: Selected right coronary artery segments were pretreated with a LPRLL balloon, delivering a dose of 0 mW during 1 min (group 1, n = 10), 50 mW during 1 min (group II, n = 10), or 100 mW during 1 min (group III, n = 10) before stenting. Quantitative coronary analysis of the stented vessel was performed before stenting, immediately after stenting, and at 6 weeks follow-up. The pigs were sacrificed, and histologic and morphometric analyses were conducted. At 6 weeks, minimal luminal stent diameter was significantly narrower in the control group compared to the 50-mW dose group (p < 0.05). These results were confirmed by morphometric analysis. Neointimal area was also significantly decreased in the 50-mW dose group. CONCLUSIONS: Intravascular LPRLL contributes to reduction of angiographic in-stent restenosis and neointimal hyperplasia in this animal model. The optimal dose using the LPRLL balloon system seems to be approximately 5 mW delivered during 1 min.

A novel platinum-iridium, potentially gamma radioactive stent: evaluation in a porcine model.

In-stent restenosis (ISR) is a major problem within stented arteries. Surface treatment of stents with platinum and gold were found to have the maximum charge with least neointima formation (NF). This study was designed to evaluate platinum (maximum electrical charge) as a material to make stents to reduce NF. Iridium was added to make an alloy suitable for stent manufacture, with the potential to make the stent radioactive. We implanted the novel platinum-iridium (PI) stent in 10 porcine coronaries and compared to the Palmaz-Schatz (PS) stent implanted in 8 coronary arteries. Six weeks after implantation, angiography of the stented vessel was performed before sacrifice. The coronaries were perfusion-fixed and stained, and vessel parameters were analyzed by computer-aided histomorphometry. The thrombus formation and the inflammatory response was less in the PI stent (0.04 +/- 0.1 vs. 0.24 +/- 0.2, P = 0.005; and 1.1 +/- 0.5 vs. 2.4 +/- 0.3, P < 0.001). The NF from PI-stented arteries was smaller in size than the PS controls (1.9 +/- 0.6 mm(2) vs. 2.4 +/- 0.4 mm(2), P = 0.06). However, PI stents presented with higher recoil than the PS stent (16% vs. 5%, P < 0.001). Platinum-iridium is a highly biocompatible material with high performance, low inflammatory response with small NF. This stent does not lead to thrombus formation and has the potential (due to the presence of iridium) to be irradiated to form a gamma radioactive stent. Cathet. Cardiovasc. Intervent. 51:364-368, 2000.

Intravascular low-power red laser light as an adjunct to coronary stent implantation: initial clinical experience.

Low-power red laser light (LPRLL) irradiation enhances endothelial cell growth in vitro and in vivo and reduces restenosis in animal models. The present study reports the preliminary clinical experience in our center. Eighty-one patients were treated with LPRLL, 30 mW/1 min, for in-stent restenosis (n = 27), elective stenting for recurrent restenosis (n = 16), and stenting for treatment of a suboptimal PTCA result (n = 38). All interventions were successful and no major adverse events due to LPRLL therapy were observed. At follow-up, 12 patients (14.8%) underwent an early control coronarogram due to target vessel restenosis. At 6 months, another 20 patients showed a significant restenosis of the target vessel. Preliminary clinical evaluation demonstrates that LPRLL is feasible and safe. The preliminary results suggest that LPRLL results in a decrease of in-stent restenosis when used during primary stenting.

Neointimal hyperplasia and late pathologic remodeling in a porcine coronary stent model.

BACKGROUND: Although coronary stenting has been demonstrated to significantly reduce restenosis compared to conventional angioplasty, occurrence of in-stent stenosis still remains one of the major limitations. This study investigates the influence of stent strut diameter on injury, inflammatory response, thrombosis and neointimal hyperplasia in a porcine coronary artery. METHODS: Coil stents made of either a 0.12 mm, 0.15 mm or 0.18 mm wire were randomly implanted in the right coronary arteries of 30 pigs. Quantitative coronary angiography analysis was performed before, immediately after, and 6 weeks following the stenting procedure. At 6 weeks, histopathology for evaluation of injury, thrombosis and inflammation, as well as morphometry for calculation of the neointimal hyperplasia and internal elastic lamina area were performed. RESULTS: Quantitative coronary analysis showed similar quantitative data before and after stent placement in the three groups. At 6 weeks, however, a significantly bigger MLD was found in the 0.18 mm group. Morphometric analysis at 6 weeks confirmed these results, showing a significantly bigger lumen area in both the 0.18 mm (1.71 +/- 0.66 mm2) and 0.15 mm (1.36 +/- 0.53 mm2) groups compared to the 0.12 mm group (0.71 +/- 0.38 mm2). The calculated neointimal hyperplasia was similar in the three groups (0.12 mm: 1.93 +/- 0.51 mm2; 0.15 mm: 1.68 +/- 0.63 mm2; and 0.18 mm: 2.16 +/- 1.48 mm2). The internal elastic membrane area, however, was significantly bigger in the 0.18 mm (3.87 +/- 1.39 mm2) compared to the 0.12 group (2.65 +/- 0.53 mm2). CONCLUSION: These results suggest that pathologic remodeling can also play an important role in late lumen loss after stent implantation.